TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial
Brief Summary: Teen girls and young women taking birth control pills may forget to take their pills or may stop taking them altogether. This places them at risk for unintended pregnancies. Most young women own cell phones and use them for text messaging. We will test whether contraceptive continuation is affected after six months of daily text message reminders.


Options:
A: Arm Label: Weekly SMS, brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Brief message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Daily SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Arm Label: Weekly SMS, Long Message; Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Services to Support ARV therapy adherence | Intervention Type: BEHAVIORAL; Name: Short Message Services to Support ARV therapy adherence; Assigned to Arm(s): Control Group, Daily SMS, Brief message, Daily SMS, Long Message, Weekly SMS, Long Message, Weekly SMS, brief message
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: EpxBreastfeeding, Other: Baby book survey | Arm Label: Control; Type: OTHER; Interventions: Other: Baby book survey | Intervention Type: OTHER; Name: EpxBreastfeeding; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Baby book survey; Assigned to Arm(s): Control, Intervention
C: Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Reminders alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone | Arm Label: Reminders + compliance-linked incentives; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reminders alone, Behavioral: Compliance-linked incentives | Intervention Type: BEHAVIORAL; Name: Reminders alone; Assigned to Arm(s): Reminders + compliance-linked incentives, Reminders alone | Intervention Type: BEHAVIORAL; Name: Compliance-linked incentives; Assigned to Arm(s): Reminders + compliance-linked incentives
D: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial
Brief Summary: Teen girls and young women taking birth control pills may forget to take their pills or may stop taking them altogether. This places them at risk for unintended pregnancies. Most young women own cell phones and use them for text messaging. We will test whether contraceptive continuation is affected after six months of daily text message reminders.


Options:
A: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: LNG-IUS (BAY 86-5028) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon) | Intervention Type: DRUG; Name: LNG-IUS (BAY 86-5028); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: 68 mg etonorgestrel implant for subdermal use (Nexplanon); Assigned to Arm(s): Arm 2
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
D: Arm Label: Contraceptive vaginal ring; Type: ACTIVE_COMPARATOR; Interventions: Device: NuvaRing | Arm Label: Oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ortho Tri-cyclen Lo | Intervention Type: DRUG; Name: Ortho Tri-cyclen Lo; Assigned to Arm(s): Oral contraceptive pill | Intervention Type: DEVICE; Name: NuvaRing; Assigned to Arm(s): Contraceptive vaginal ring

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Inhaled Hypertonic Saline to Reduce Hospital Admissions in Infants With Viral Bronchiolitis (HS in ER Study)
Brief Summary: Inhaled 3% hypertonic saline (HS) administered every 2-8 hours to infants admitted to hospital with viral bronchiolitis has been shown to improve airway clearance and reduces length of stay.

Hypothesis: When infants first present to the ER, frequent administration of HS over a brief time period will provide significant symptom improvement such that the need for hospital admission will be reduced.

Objective: To determine in a randomized, controlled and double-blind fashion if the short term intensive use of inhaled 3% hypertonic saline (HS) in the Emergency Room (ER) can reduce the rate of hospital admission for infants presenting with moderately severe viral bronchiolitis.


Options:
A: Arm Label: Treatment 1. 5% Saline + Epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Treatment 1. (5% Hypertonic saline + Epinephrine) | Arm Label: Treatment 3. 3% Saline + Epinephrine; Type: OTHER; Interventions: Drug: Treatment 3. (3% Hypertonic saline + Epinephrine) | Arm Label: Treatment 2 . 0.9% Saline + Epinephrine; Type: OTHER; Interventions: Drug: Treatment 2. (Normal saline + Epinephrine) | Intervention Type: DRUG; Name: Treatment 1. (5% Hypertonic saline + Epinephrine); Assigned to Arm(s): Treatment 1. 5% Saline + Epinephrine | Intervention Type: DRUG; Name: Treatment 3. (3% Hypertonic saline + Epinephrine); Assigned to Arm(s): Treatment 3. 3% Saline + Epinephrine | Intervention Type: DRUG; Name: Treatment 2. (Normal saline + Epinephrine); Assigned to Arm(s): Treatment 2 . 0.9% Saline + Epinephrine
B: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% saline; Assigned to Arm(s): Nebulized 0.9% Saline
C: Arm Label: Normal saline and epinephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Normal saline and epinephrine | Arm Label: Hypertonic saline and epinephrine; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Hypertonic saline and epinephrine; Assigned to Arm(s): Hypertonic saline and epinephrine | Intervention Type: DRUG; Name: Normal saline and epinephrine; Assigned to Arm(s): Normal saline and epinephrine
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 3% hypertonic saline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: solution contains 1 mg salbutamol plus 0.9% saline | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 3% hypertonic saline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: solution contains 1 mg salbutamol plus 0.9% saline; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Pack Supply on Oral Contraception Continuation
Brief Summary: The purpose of this study is to determine whether getting more packs of birth control pills leads to improved continuation, when compared with getting the traditional supply.


Options:
A: Arm Label: Mobile phone-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone-based intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone-based intervention; Assigned to Arm(s): Mobile phone-based intervention
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
C: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: enhanced initial supply of oral contraception | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional initial supply of oral contraception | Intervention Type: OTHER; Name: enhanced initial supply of oral contraception; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional initial supply of oral contraception; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Extension to a 26-week Treatment, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless, Parallel-group Study to Assess Safety, Tolerability and Efficacy of Two Doses of Indacaterol (150 and 300 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: This study evaluated the 1 year safety, tolerability and efficacy of indacaterol against placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients


Options:
A: Arm Label: FF/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder, FF/GW642444 Inhalation Pwdr | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Indacaterol 150 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol | Arm Label: Indacaterol 300 µg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 150 µg, Indacaterol 300 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tiotropium; Type: OTHER; Interventions: Drug: Tiotropium | Arm Label: Placebo; Type: OTHER; Interventions: Device: Respimat | Intervention Type: DEVICE; Name: Respimat; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa
Brief Summary: The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P. falciparum in children in African countries.


Options:
A: Arm Label: 1AZ+AQ; Type: EXPERIMENTAL; Interventions: Drug: azithromycin + artesunate | Arm Label: 2AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: artemether-lumefantrine | Intervention Type: DRUG; Name: azithromycin + artesunate; Assigned to Arm(s): 1AZ+AQ | Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): 2AL
B: Arm Label: Azithromycin + Artesunate; Type: EXPERIMENTAL; Interventions: Drug: azithromycin plus artesunate | Arm Label: Artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate | Intervention Type: DRUG; Name: azithromycin plus artesunate; Assigned to Arm(s): Azithromycin + Artesunate | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): Artesunate
C: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin plus Chloroquine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Azithromycin plus Chloroquine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial to Investigate an Educational Programme and Continuous Monitoring to Prevent Diabetes in Individuals With Screen Detected Pre-diabetes in a Multi-ethnic Population
Brief Summary: The study aims to identify people at high diabetes risk within the local population and then implement and evaluate a pragmatic and low-cost diabetes prevention programme containing structured education on lifestyle, physical activity and food choices. An ongoing support framework will continue to reinforce and maintain the participant's individual goals to prevent the development of diabetes and reduce cardiovascular risk.

Therefore the principal question is: can we significantly reduce the incidence of diabetes through structured education in a high risk multi-ethnic UK population?


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Procedure: optimised treatment | Intervention Type: PROCEDURE; Name: optimised treatment; Assigned to Arm(s): Intervention
B: Arm Label: Blood Test Group; Type: EXPERIMENTAL; Interventions: Behavioral: Blood Test Group Intervention | Arm Label: Brochure Group (usual care); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brochure Group Intervention | Intervention Type: BEHAVIORAL; Name: Blood Test Group Intervention; Assigned to Arm(s): Blood Test Group | Intervention Type: BEHAVIORAL; Name: Brochure Group Intervention; Assigned to Arm(s): Brochure Group (usual care)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1
D: Arm Label: Intensive Treatment; Type: OTHER; Interventions: Drug: multi-factorial intervention | Intervention Type: DRUG; Name: multi-factorial intervention; Assigned to Arm(s): Intensive Treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial to Investigate an Educational Programme and Continuous Monitoring to Prevent Diabetes in Individuals With Screen Detected Pre-diabetes in a Multi-ethnic Population
Brief Summary: The study aims to identify people at high diabetes risk within the local population and then implement and evaluate a pragmatic and low-cost diabetes prevention programme containing structured education on lifestyle, physical activity and food choices. An ongoing support framework will continue to reinforce and maintain the participant's individual goals to prevent the development of diabetes and reduce cardiovascular risk.

Therefore the principal question is: can we significantly reduce the incidence of diabetes through structured education in a high risk multi-ethnic UK population?


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational text messaging | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational text messaging; Assigned to Arm(s): Intervention Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mini Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Mini Booster | Arm Label: Full Booster; Type: EXPERIMENTAL; Interventions: Behavioral: Full Booster | Intervention Type: BEHAVIORAL; Name: Mini Booster; Assigned to Arm(s): Mini Booster | Intervention Type: BEHAVIORAL; Name: Full Booster; Assigned to Arm(s): Full Booster
D: Arm Label: 10,000 step/day recommendation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 10,000 step/day recommendation | Arm Label: Adaptive recommendation; Type: EXPERIMENTAL; Interventions: Behavioral: Adaptive step recommendation | Intervention Type: BEHAVIORAL; Name: Adaptive step recommendation; Assigned to Arm(s): Adaptive recommendation | Intervention Type: BEHAVIORAL; Name: 10,000 step/day recommendation; Assigned to Arm(s): 10,000 step/day recommendation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial to Investigate an Educational Programme and Continuous Monitoring to Prevent Diabetes in Individuals With Screen Detected Pre-diabetes in a Multi-ethnic Population
Brief Summary: The study aims to identify people at high diabetes risk within the local population and then implement and evaluate a pragmatic and low-cost diabetes prevention programme containing structured education on lifestyle, physical activity and food choices. An ongoing support framework will continue to reinforce and maintain the participant's individual goals to prevent the development of diabetes and reduce cardiovascular risk.

Therefore the principal question is: can we significantly reduce the incidence of diabetes through structured education in a high risk multi-ethnic UK population?


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control arm (usual care/standard care arm) | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental | Intervention Type: BEHAVIORAL; Name: Experimental; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control arm (usual care/standard care arm); Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified DESMOND education and ongoing support | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Modified DESMOND education and ongoing support; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle counselling | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle counselling; Assigned to Arm(s): 1
D: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib
Brief Summary: Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib, Drug: AMG 386 placebo IV | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Sorafenib | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: AMG 386 placebo IV | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 placebo IV; Assigned to Arm(s): Arm A, Arm C
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
C: Arm Label: 1: AGS-003+sunitinib; Type: EXPERIMENTAL; Interventions: Biological: AGS-003, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): 1: AGS-003+sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1: AGS-003+sunitinib
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon Alfa | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: CCI-779 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa and CCI-779 | Intervention Type: DRUG; Name: Interferon Alfa; Assigned to Arm(s): A | Intervention Type: DRUG; Name: CCI-779; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon Alfa and CCI-779; Assigned to Arm(s): C

Answer: C